No Data
No Data
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
Boundless Bio's Q3 2024: Advancing Cancer Therapies
Express News | Boundless Bio Q3 2024 GAAP EPS $(0.74) Beats $(0.82) Estimate
Express News | Boundless Bio Inc Q3 Shr View $-0.75 -- LSEG IBES Data
Boundless Bio | 10-Q: Q3 2024 Earnings Report
No Data
No Data
73264095 : Nice, thanks! You think UMAC is done? looked like it held up pretty well in AH
Jaguar8 OP 73264095 : Nope. I feel it will still go
Jaguar8 OP 73264095 : I have not yet finished the list
Huaw : Will the rejection of APLT approval cause such a significant decline? Is it this serious?
Jaguar8 OP Huaw : It was just a CRL meaning they can’t approve at the moment due to some deficiencies which the company will address and will resubmit
View more comments...